IL-17

      Treatment of Enthesitis: Dr. Robert Chao
      4 years ago
      unhappy%20patient.jpg
      How do we personalize psoriatic arthritis treatment?
      4 years ago
      It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it? Oral presentation (6937) discussed that issue and addressed our need for a more personalized approach to the treatment of PsA. 
      RT @MeralElRamahiMD: ➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      ➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus
      RT @MeralElRamahiMD: ⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX)
      -Tx . (TP)1: SEC 75/100 m

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      ⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX) -Tx . (TP)1: SEC 75/100 mg till wk 12 -TP2: cont SEC or switch to PBO till wk 104 ⭐️SEC efficacious on JIA ACR30/70 ⭐️74% w/ resolution of enthes ⭐️Median T2flare in PBO in TP2 = 453d LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6
      The PsA SpA Paradox of Choice: Dr. Rachel Tate
      4 years ago
      Real World Data in AxSpA and PsA: Dr. Rachel Tate
      4 years ago
      EULAR 2021 - Day 2 Podcasts

      Check out this compilation of our EULAR 2021 Day 2 broadcasts below.

      You can also follow t

      Dr. John Cush RheumNow

      4 years ago
      EULAR 2021 - Day 2 Podcasts Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud. https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
      RT @ejdein1: #EULAR2021 LB0004: Secukinumab for enthesitis-related JIA treatment-withdrawal study shows longer time to f

      Eric Dein ejdein1

      4 years ago
      #EULAR2021 LB0004: Secukinumab for enthesitis-related JIA treatment-withdrawal study shows longer time to flare and decreased flares compared to PBO @Rheumnow https://t.co/LG3dDmH7we
      RT @doctorRBC: JUNIPERA - secukinumab in enthesitis related arthritis and juvenile PsA
      ⭐️achieved JIA ACR response c

      Robert B Chao, MD doctorRBC

      4 years ago
      JUNIPERA - secukinumab in enthesitis related arthritis and juvenile PsA ⭐️achieved JIA ACR response compared to placebo ⭐️⬇️time to flare ⭐️75% with resolution of enthesitis ⭐️0 deaths, AE - minor infections, GI issues, headache Abs#LB0004 #EULAR2021 @RheumNow
      RT @uptoTate: SPIRIT-P1&P2 studies showed IXE effective in treating axPsA. When do you consider IL17i in your treatm

      Dr. Rachel Tate uptoTate

      4 years ago
      SPIRIT-P1&P2 studies showed IXE effective in treating axPsA. When do you consider IL17i in your treatment algorithm in axPsA (as the predominant domain?) Poster #POS1045 #EULAR2021 @RheumNow
      RT @uptoTate: SPIRIT-P1&P2: IXE is effective in⬇️axial symptoms & improving QoL in active PsA pts with axial

      Dr. Rachel Tate uptoTate

      4 years ago
      SPIRIT-P1&P2: IXE is effective in⬇️axial symptoms & improving QoL in active PsA pts with axial involvement. Abstract #POS1045 #EULAR2021 @RheumNow https://t.co/GC78Lmp9cH https://t.co/WfaUqIRrY6
      Nr-axSpA vs axSpA — does it matter? Dr. Meral El Ramahi
      4 years ago
      RT @uptoTate: PREVENT: SEC 150 mg showed durable improvement in nr-axSpA through 2 yrs, 438 pts. No new or unexpected

      Dr. Rachel Tate uptoTate

      4 years ago
      PREVENT: SEC 150 mg showed durable improvement in nr-axSpA through 2 yrs, 438 pts. No new or unexpected safety signals. Poster #POS0900 #EULAR2021 @RheumNow https://t.co/NU1EO9zktn https://t.co/LP3hkZodhi
      RT @AurelieRheumo: JUNIPERA trial: open label Secukinumab in ERA and JPsA: 90.4% JIA ACR 30 and 69.9% JIA ACR 70 W12 and

      Aurelie Najm AurelieRheumo

      4 years ago
      JUNIPERA trial: open label Secukinumab in ERA and JPsA: 90.4% JIA ACR 30 and 69.9% JIA ACR 70 W12 and > time to flare W104, 72% risk of flare reduction SEC vs PBO (HR: 0.28 95CI: 0.13–0.63 P<0.001). No particular safety signal. #LB0002 @Rheumnow #EULAR2021 https://t.co/PJ9NYi25UI
      RT @MeralElRamahiMD: 2021 GRAPPA STRONG recs (cont'd):
      *⃣Crohn's Dz &amp; UC: TNFi (not ETN), IL12/23i
      🚫strong rec

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years ago
      2021 GRAPPA STRONG recs (cont'd): *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i 🚫strong rec against IL17i 2021 GRAPPA CONDITIONAL recs for: *⃣ Uveitis: TNFi (not ETN), CyA *⃣ Crohn's Dz & UC: IL23i, JAKi, MTX OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG

      Catch up on Conference Podcasts

      ×